BioVie Targets Alzheimer’s, Parkinson’s & Long COVID With Breakthrough Drug Bezisterm

BioVie CEO Cuong Do outlines the company’s bold vision to tackle major diseases including Alzheimer’s, Parkinson’s, and Long COVID using its lead drug candidate Bezisterm, a novel inflammation modulator. Early clinical results show promising safety and efficacy, including slowed cognitive decline in Alzheimer’s patients and improved motor control in Parkinson’s, positioning the drug as a potential breakthrough therapy.

With multiple clinical trials underway and key data readouts expected soon, BioVie is targeting massive market opportunities across several unmet medical needs. The company also highlights strong institutional support, ongoing Phase 2 and Phase 3 trials, and the potential for accelerated regulatory pathways as it advances toward commercialization.

#BioVie
#Biotech
#Alzheimers
#Parkinsons
#LongCOVID
#DrugDevelopment
#ClinicalTrials
#BiotechInvesting
#HealthcareInnovation
#MedicalBreakthrough
#Inflammation
#Pharmaceuticals
#FDA
#Nasdaq
#BIVI